Abstract MicroRNAs (miRNAs) are a class of 20-24 nt small non-coding RNAs that regulate a wide range of biological processes through changing the stability and translation of their target messenger RNA (mRNA) genes. Shortly after their identification, many miRNA genes have been found dysregulated in a variety of human cancers, indicating a pathological function of this gene class in mediating cancer progression. Over the past decade, accumulated literature has shown that miRNAs participate in numerous cancer-relevant processes including cell proliferation, apoptosis, differentiation, metabolism, and importantly, metastasis, which accounts for the mortality of approximately 90 % of cancer patients. Several recent publications have linked miRNAs with metastasis-associated protein (MTA) family members. Given the fact that the MTA family members are widely overexpressed in human cancers and their nature of serving as both corepressor and coactivator in gene regulation, it is intriguing to study whether certain miRNAs regulate cancer progression through modulating the expression of MTA family members. In this review, we will focus on recent advances in understanding the regulatory relationship between certain miRNAs and MTA family members.
miRNAs and cancer
With the development of next-generation sequencing techniques, a previously unrecognized world of non-coding RNA molecules have been recently discovered [1] . MicroRNAs (miRNAs), the best-characterized non-coding RNA family with about 1400 members in the human genome, have been shown to be involved in almost all the biological processes that have ever been studied [2] . In addition to their important roles in development and maintaining physiological tissue homeostasis [3] , dysregulation of miRNAs have been implicated in multiple pathological processes including cancer [4] [5] [6] . Decided by the specific cellular context, miRNAs can either function as oncogenes that overexpressed in tumors to facilitate tumorigenesis or as tumor suppressors that downregulated in tumors [7] [8] [9] . Importantly, many miRNAs have been shown to regulate the metastatic process, which accounts for the mortality of approximately 90 % of cancer patients [10, 11] .
Although there are still debates on certain aspects of miRNA biogenesis and their functional mechanisms, the key processes have been clearly characterized [12] . Majority of miRNAs genes are transcribed by RNA polymerase II, either as an individual transcriptional unit or embedded within the introns of protein-coding genes. These transcriptional products, named as pre-miRNAs, are trimmed inside the nucleus by the microprocessor complex containing RNase III enzyme Drosha, yielding an approximately 70-nt long precursor (premiRNA) with a hairpin structure. Pre-miRNAs are subsequently exported to the cytoplasm by exportin 5 (XPO5), where they are further processed into 19-25 nt miRNA duplexes by a protein complex containing RNase III protein Dicer. In most cases, the less stable strand in the miRNA duplex is incorporated into the RNA-induced silencing complex (RISC), which contains several key proteins such as Argonaute (Ago) and GW182. The mature miRNA then guides the miRNA-RISC complex to its target messenger RNA (mRNA) through sequence recognition and induces post-transcriptional gene silencing by tethering RISC to these target mRNAs [13] [14] [15] .
After human miRNAs were discovered, it was soon noticed that many miRNA genes were located at fragile sites in the genomic region that frequently amplified or deleted in human cancers [16] . In addition, expression analysis using genome-wide microarray and sequencing techniques in a wide spectrum of cancer types have evidenced that aberrant miRNA expression is commonly found in these diseases [5, 17] . To answer the question whether the change of miRNA expression is a cause or consequence of cancer progression, multiple groups have provided mechanistic explanations that many miRNAs function as causal genes in cancer development. For example, the miR-17-92 cluster, known as the first noncoding oncogene and referred to as oncomir-1, has been found commonly amplified in many types of malignancies including B cell lymphoma, T cell lymphoma, colorectal cancer, breast cancer, hepatocellular carcinoma, and osteosarcoma [18] [19] [20] [21] [22] [23] . The miRNAs contained in this cluster promotes cell proliferation and suppress cell apoptosis through various pathways [24] . They also function as mediators of angiogenesis that induced by the oncogene c-Myc in tumors [25] . On the other hand, the let-7 family of miRNAs was among the first identified miRNAs that suppress the expression of oncogenes and act as tumor suppressors. In lung cancer cells, let-7 inhibits the proto-oncogene Ras expression and its downregulation correlates significantly with a poor patient prognosis [26] . Now, we know that there is a global decrease in miRNA expression in tumor tissues comparing with their corresponding normal tissues, reflecting a degree of less cell differentiation [5, 27] . In addition to this general trend, certain miRNAs function as master regulators, either as oncogenes or tumor suppressors, in cancer progression. Many of these miRNAs also play a role beyond the tumor-initiating process and directly regulate tumor metastasis [28] [29] [30] through both changing the intrinsic properties of cancer cells and shaping the interactions between cancer cells and other components of the tumor microenvironment [31] . Differing from protein coding genes, the exact function of a given miRNA is highly dependent on the cellular context, such as the relative expression of target genes present in the cell and the level of certain RNAbinding proteins that regulate miRNA-target interactions. This characterization of miRNAs provides a possibility that, through analyzing the gene expression pattern of a specific patient, miRNAs may serve as patient "tailored" diagnostic markers or anticancer agents and provide a toolbox in personalized treatment of cancer patients.
MTA family members in cancer progression
Metastasis-associated proteins (MTAs, or metastatic tumor antigens) are a small protein family encoded by three distinct genes in human genome [32, 33] . The founding member of this protein family, MTA1, was first identified in 1994 through a differential complementary DNA (cDNA) library screening comparing mRNA expression levels in rat mammary adenocarcinoma cell lines with different metastatic abilities [34] . MTA1 displays a much higher expression level in highly metastatic cells than in nonmetastatic cells. The nomenclature of this protein family clearly reflects the origin of their discovery. Although the importance of MTA1 in tumor progression was recognized early, its molecular function remains elusive until 1998, when a proteomic study revealed MTA1 as an integral component of the nucleosome remodeling and histone deacetylation (NuRD) complexes [35] . The NuRD complex is a multi-subunit protein complex containing both histone deacetylase and nucleosome-dependent ATPase subunits [36] . In the current understanding of gene regulation, NuRD complex can be recruited into specific gene region through protein-protein interactions or protein-DNA interactions and silence gene transcription by deacetylation of associated histones [37] . Interestingly, several subunits of this complex, particularly the MTA family members, present heterogeneity at the protein level. A hypothesis has been proposed that incorporation of specific subunits into the complex might determine the functional specialization of the complex itself [38] . The three MTA genes in human genome encode at least six protein products (MTA1, MTA1s, MTA1-ZG29p, MTA2, MTA3, and MTA3L) that have non-redundant functions [32] . To date, several studies have been published to support the notion that MTA proteins are able to specify the function of NuRD complexes in the context of cancer [39] . For example, MTA3 has been found to incorporate into the NuRD complex and repress the expression of Snail, a master transcription regulator of epithelial to mesenchymal transition (EMT) and plays an important role in mediating cancer metastasis. However, MTA1 or MTA2 are unable to substitute for MTA3 and regulate Snail expression [40] .
As an integral component of the NuRD complex, MTA proteins suppress the expression of a number of tumor suppressor genes and thus contribute to cancer cell transformation and invasion. For example, MTA1 has been reported to transform Rat1 fibroblasts through suppressing Gi2α expression in a NuRD complex-dependent manner and resulting in a profound stimulation of the Ras pathway [41] . Similarly, MTA1-NuRD complex has also been found to associate with the Ecadherin gene in a specific cell state and suppress its transcription. Since E-cadherin plays an essential role in epithelial cell adhesion, MTA1 thus directly contributes to EMT and cancer cell invasion [42] . Additionally, MTA1 also interacts with ERα and thus represses ERα transcriptional activity through guiding NuRD complex to ERα target genes [43] . It should be noted that MTA-containing NuRD complexes are also capable of deacetylation of non-histone proteins. In the context of cancer, two well-studied cancer regulators, p53 and HIF1α, have been found as substrates of NuRD complexes and recognized by different MTA family proteins. The p53 tumor suppressor interacts with MTA2 directly and is significantly deacetylated via this interaction. Deacetylation of p53 marks it for degradation through the MDM2 pathway and results in a decrease of p53-dependent transcription [44] . Differently, HIF1α interacts with MTA1 and is deacetylated by the MTA1-containing NuRD complex. Deacetylation of HIF1α actually increases its stability and promotes cell survival in hypoxic conditions [45] .
In the past few years, more evidence has emerged on the molecular mechanisms of how MTA family proteins regulate cancer progression. Surprisingly, multiple studies demonstrated that MTA proteins were able to function as a coactivator of gene expression, when not in association with the NuRD complex, and changed the conventional paradigm of MTA function. The first piece of evidence showing the coactivator role of MTA comes from the regulation of breast cancer amplified sequence 3 (BCAS3) gene by MTA1 [46] . In MCF7 cells, MTA1 protein is acetylated at its lysine 626 site and thus obtains the ability to recruit RNA polymerase II complex to the BCAS3 gene promoter. Because of the oncogenic role of BCAS3, MTA1 promotes the malignant phenotypes of this breast tumor cell line through the MTA1-BCAS3 pathway [46] . A similar regulation has been reported in B cells as well. In this case, acetylated MTA1 was directly recruited to the promoter of Pax5, a transcription factor with oncogenic function in B cell lymphogenesis, and facilitate its expression [47, 48] . In addition, more recent studies have connected MTA1 with inflammation [49] [50] [51] , a process studied in the context of cancer for a long time because persistent inflammation contributes to the initiation and development of cancerous phenotypes [52, 53] . By studying the MTA1 expression and function in macrophages, Pakala and colleagues found that MTA1 was a direct target of NF-κB, the central transcriptional regulator in inflammation response. Moreover, in stimulated macrophages, the association of MTA1 with other NuRD complex subunits was impaired due to unclear reasons; and MTA1 functioned as a coactivator for multiple inflammatory cytokines including IL-1β and TNFα in this situation [49] .
MTA family genes regulated by miRNAs
The illustration of distinctive function of different MTA family members and the emergence of evidence showing the biregulatory role of MTA proteins as both corepressor and coactivator raise many questions on how to fully understand their biological function in cancer development. For example, with a given number of existing NuRD complexes in a cell, do MTA proteins compete with each other for their incorporation? If this is the case, do relative expression levels of MTA proteins determine which subsets of genes to be repressed? Is acetylation of MTA1 the only factor to determine the switch from corepressor to coactivator? Is there a threshold of MTA1 expression, for example, when the number of MTA1 proteins exceeds the need to form NuRD complexes, to start acetylation and switch to coactivator? To answer these questions, a complete understanding of transcriptional and posttranscriptional regulation of MTA genes is necessary. Recently, several studies suggested a link between certain miRNAs with MTA protein expression levels [54] [55] [56] [57] [58] [59] [60] . Given the fact that miRNAs can act as "rheostats" to fine-tune protein expression in subtle magnitude [61, 62] , it is intriguing to investigate whether certain miRNAs can function as the mediators to decide the functional mode of MTA proteins.
The first piece of evidence of miRNA regulating MTA family proteins was found in breast cancer cells (Table 1 ). In 2009, Reddy et al. reported that miR-661 directly recognizes the 3 UTR of MTA1 mRNA and thus represses MTA1 expression at the protein level [54] . miR-661 is positively regulated by transcription factor c/EBPα, a tumor suppressor that is frequently downregulated in breast cancer cells. As a result, downregulation of c/EBPα in breast cancer cells leads to a decreased miR-661 expression and an enhanced MTA1 protein level. In addition, ectopic expression of miR-661 significantly compromised cancer cell invasion and anchorageindependent growth [54] . Without regulating other MTA family members, miR-661 specifically suppresses MTA1 expression; but it is unclear whether alteration of this miRNA will lead to a redistribution of NuRD complexes on different genomics regions. Interestingly, the same group found that the miR-661-MTA1 pathway is conserved in hepatocellular carcinoma cells infected by hepatitis B virus (HBV) [55] . In these cells, HBx, a major regulator of cellular responses encoded by HBV, induces MTA1 expression through suppressing miR-661 expression [55] . Additional miRNAs have been found to regulate the expression of MTA1. Using endometrial cancer cells as an experimental system, Zhou et al. reported that miR-30c negatively regulated MTA1 and suppressed cancer cell proliferation and migration [58] . The miR30c-MTA1 pathway has also been found in non-small cell lung cancer (NSCLC) cells, demonstrating its functional importance in different cancer types [59] .
In 2010, Li et al. reported that miR-146a suppressed MTA2 expression in pancreatic cancer cells [56] . MTA2 was among a group of proteins that were simultaneously suppressed by miR-146a and contributed to cell invasion [56] . In addition, [60] miR-34a, a well-studied miRNA in the context of cancer as a direct target of p53 and induces cell cycle arrest [63] , has been found to suppress MTA2 at both the mRNA and protein levels [57] . This downregulation is believed to form a positive feedback loop of p53 and miR-34a since MTA2 deacylated p53 and induced its degradation [57] . Recently, MTA3 has also been found as a direct target of miRNA regulation. In NSCLC cells, miR-495 directly suppresses MTA3 at the protein level and thus compromises cancer cell proliferation and migration [60] . Importantly, a correlation between miR-495 and MTA3 has been observed in a cohort of 56 NSCLC patient tissue samples [60] . As another aspect of the miRNA-MTA relationship, MTA1 has been found to regulate the expression of a group of miRNAs in NSCLC cells [64] . One of these miRNAs, miR-125b, is reported as an important mediator for MTA1 to promote NSCLC cell migration and invasion [65] . However, the mechanism of how MTA1 regulates miRNA expression is still unknown. It is also unclear if miRNA-MTA can form regulatory feedback loops to maintain a bistable state. The study of miRNAs that regulate MTA family proteins is still in its nascent stage. Although several miRNAs have been validated as bona fide regulators of MTA proteins as discussed above, experiments that sophisticatedly designed to test the effects of the miRNA-MTA pathway on targets selection of NuRD complexes are still lacking. In addition, given the fact that there are additional naturally occurring MTA variants such as MTA1s, which is generated by alternative splicing of MTA1 gene and mainly functions in the cytoplasm to sequester ERα [66] , it is worth exploring if certain miRNAs regulate cancer progression through specifically modulating these variants derived from differential splicing events. Moreover, currently, it is totally unknown whether miRNAs may play a role in the functional switch of MTA1 protein from acting as a corepressor to acting as a coactivator. Studies intend to answer these questions may provide central pieces of evidence to understand the biological functions of MTA proteins in cancer progression.
Concluding remarks
Since the cloning of MTA1 cDNA in 1994 [34] , the past two decades have observed the dramatic expansion of our understanding in the molecular details of MTA family members' functions. Recent studies demonstrating the bi-regulatory nature of MTA1 challenged the conventional paradigm of MTA function and raised many questions in fully understanding their roles in cancer progression. In the meantime, although several reports have identified certain miRNAs as regulators of different MTA family proteins, a complete analysis of the impact of MTA regulating miRNAs at the genome level is still needed. In addition, the effects of MTA regulating miRNAs on the corepressor-coactivator switch remain mysterious. Given the important functions of MTA family proteins in a variety of cancer types, answering these important questions may provide opportunities in the future to develop miRNA-based therapies that benefit cancer patients through modulating the functional status of MTA proteins.
